University of Antwerp-ko ikertzaileekin lankidetzan egindako argitalpenak (19)

2024

  1. Involvement of the choroid plexus in Alzheimer’s disease pathophysiology: findings from mouse and human proteomic studies

    Fluids and Barriers of the CNS, Vol. 21, Núm. 1

  2. Paired plasma lipidomics and proteomics analysis in the conversion from mild cognitive impairment to Alzheimer's disease

    Computers in Biology and Medicine, Vol. 176

2023

  1. Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning

    Genome Medicine, Vol. 15, Núm. 1

  2. Whole-exome rare-variant analysis of Alzheimer's disease and related biomarker traits

    Alzheimer's and Dementia, Vol. 19, Núm. 6, pp. 2317-2331

2022

  1. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease

    Molecular neurodegeneration, Vol. 17, Núm. 1, pp. 27

  2. Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (Molecular Neurodegeneration, (2022), 17, 1, (27), 10.1186/s13024-022-00521-3)

    Molecular Neurodegeneration

  3. Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition

    Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 14, Núm. 1

  4. Genome-Wide Association Study of Alzheimer’s Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery Dataset

    Frontiers in Aging Neuroscience, Vol. 14

  5. Predicting AT(N) pathologies in Alzheimer’s disease from blood-based proteomic data using neural networks

    Frontiers in Aging Neuroscience, Vol. 14

  6. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum

    JAMA Neurology, Vol. 79, Núm. 3, pp. 228-243

  7. Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation

    Molecular Psychiatry, Vol. 27, Núm. 4, pp. 1990-1999

2021

  1. Sex-specific metabolic pathways were associated with alzheimer’s disease (Ad) endophenotypes in the european medical information framework for ad multimodal biomarker discovery cohort

    Biomedicines, Vol. 9, Núm. 11

  2. TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels

    Alzheimer's and Dementia, Vol. 17, Núm. 10, pp. 1628-1640

2020

  1. Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology

    Journal of Alzheimer's Disease, Vol. 77, Núm. 3, pp. 1353-1368

  2. Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset

    Translational Psychiatry, Vol. 10, Núm. 1

  3. Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort

    Journal of Alzheimer's Disease, Vol. 74, Núm. 1, pp. 213-225

2019

  1. A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort

    Alzheimer's and Dementia: Translational Research and Clinical Interventions, Vol. 5, pp. 933-938

  2. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

    Alzheimer's and Dementia, Vol. 15, Núm. 11, pp. 1478-1488

2018

  1. The EMIF-AD Multimodal Biomarker Discovery study: Design, methods and cohort characteristics

    Alzheimer's Research and Therapy, Vol. 10, Núm. 1